Published in Cancer Weekly, May 1st, 1995
The company will also launch Photofrin, porfimer sodium, in Canada for the treatment of superficial bladder cancer later in 1995. Both drugs will be marketed through its newly formed subsidiary, Ligand Pharmaceuticals (Canada) Inc. (LCI).
"Ligand has established its business presence in Canada through the exclusive licensing of its first two anticancer products. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.